NeuroBo Pharmaceuticals, Inc. (NRBO) Bundle
An Overview of NeuroBo Pharmaceuticals, Inc. (NRBO)
General Summary of NeuroBo Pharmaceuticals, Inc. (NRBO)
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for various metabolic diseases. The company was founded in 2018 and is headquartered in Boston, Massachusetts. Its primary focus is on developing treatments for metabolic diseases, including obesity and diabetes, leveraging its proprietary compounds.
As of 2024, NeuroBo's main products include:
- DA-1241: A treatment for metabolic dysfunction-associated steatotic liver disease (MASH).
- DA-1726: A treatment for obesity and related metabolic conditions.
In 2024, NeuroBo Pharmaceuticals reported total sales revenue of approximately $3.0 million from product sales, reflecting its ongoing clinical trials and development efforts.
Company's Financial Performance in the Latest Financial Reports
In the most recent financial reports, NeuroBo Pharmaceuticals demonstrated significant growth in operating metrics. For the nine months ended September 30, 2024, the company reported:
| Financial Metrics | 2024 (9 Months) | 2023 (9 Months) | Change (%) |
|---|---|---|---|
| Operating Expenses | $23.2 million | $10.2 million | 127.3% |
| Research and Development Expenses | $17.5 million | $5.3 million | 230.5% |
| General and Administrative Expenses | $5.7 million | $4.9 million | 16.3% |
| Net Loss | $22.4 million | $7.2 million | 211.1% |
| Loss per Share | $3.24 | $1.41 | 129.1% |
As of September 30, 2024, NeuroBo had cash reserves totaling $21.7 million, down from $25.8 million at the same point in 2023. The company incurred a net cash used in operating activities of $19.3 million during the nine months ended September 30, 2024, compared to $7.4 million for the same period in 2023.
Introduction to NeuroBo Pharmaceuticals as a Leader in the Industry
NeuroBo Pharmaceuticals is recognized as a leader in the biopharmaceutical sector, particularly in the development of treatments for metabolic diseases. The company has made significant strides in its clinical trials, particularly with DA-1241 and DA-1726, underlining its commitment to addressing unmet medical needs in obesity and metabolic disorders.
NeuroBo's collaborative efforts, such as its partnership with Dong-A ST Co., Ltd. for the development of its proprietary compounds, further solidify its position in the industry. The company's ongoing clinical trials are expected to enhance its product pipeline, aiming for regulatory approvals that could pave the way for future revenue streams and market expansion.
Mission Statement of NeuroBo Pharmaceuticals, Inc. (NRBO)
Mission Statement of NeuroBo Pharmaceuticals, Inc. (NRBO)
The mission statement of NeuroBo Pharmaceuticals, Inc. (NRBO) is a critical element that guides the company's long-term goals and strategic initiatives. It articulates the company's commitment to developing innovative therapies for unmet medical needs, particularly in the fields of metabolic diseases and neurodegenerative disorders. This mission serves not only as a guiding principle but also as a benchmark against which the company measures its success and progress in the healthcare landscape.
Core Component 1: Innovation in Therapeutics
NeuroBo is dedicated to pioneering advancements in medical science. The focus on innovation is reflected in their investment in research and development (R&D), which reached approximately $17.5 million for the nine months ended September 30, 2024, a significant increase of 230.5% compared to $5.3 million during the same period in 2023. This substantial investment underscores NeuroBo's commitment to discovering and developing novel therapies, particularly their ongoing clinical trials for DA-1241 and DA-1726, which target metabolic and neurodegenerative diseases.
Core Component 2: Commitment to Quality
Quality is at the heart of NeuroBo's mission. The company is committed to ensuring that all products meet rigorous standards of safety and efficacy. For example, during the three months ended September 30, 2024, NeuroBo reported total operating expenses of $6.3 million, reflecting their dedication to maintaining high-quality processes in both R&D and administrative functions. Furthermore, the company has established partnerships, such as the Shared Services Agreement with Dong-A, to leverage expertise in clinical trial support and drug manufacturing, further enhancing their quality assurance frameworks.
Core Component 3: Addressing Unmet Medical Needs
NeuroBo Pharmaceuticals is focused on addressing significant unmet medical needs, particularly in the treatment of metabolic diseases and neurodegenerative disorders. As of September 30, 2024, the company had an accumulated deficit of $130.7 million, indicating the extensive resources allocated towards the development of therapies that could transform patient outcomes. The ongoing Phase 2a clinical trial for DA-1241 demonstrates NeuroBo's proactive approach to filling gaps in current treatment options, aiming to enhance the quality of life for patients suffering from these conditions.
| Financial Metrics | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Research and Development Expenses | $17.5 million | $5.3 million |
| Total Operating Expenses | $23.2 million | $10.2 million |
| Net Loss | $22.4 million | $7.2 million |
| Accumulated Deficit | $130.7 million | $108.3 million |
| Cash Position | $21.7 million | $25.8 million |
Conclusion
The mission statement of NeuroBo Pharmaceuticals encapsulates the company's dedication to innovation, quality, and addressing unmet medical needs, guided by a strategic focus on R&D investments and operational excellence. This commitment is reflected in their financial performance and ongoing clinical initiatives, positioning NeuroBo as a forward-thinking entity in the pharmaceutical industry.
Vision Statement of NeuroBo Pharmaceuticals, Inc. (NRBO)
Vision Statement Overview
NeuroBo Pharmaceuticals, Inc. (NRBO) envisions a future where innovative therapeutics significantly improve the quality of life for patients suffering from metabolic and neurodegenerative diseases. The company aims to lead the biopharmaceutical industry in developing groundbreaking treatments through robust research and development efforts.
Commitment to Innovation
At the core of NeuroBo's vision is a strong commitment to innovation. The company is actively engaged in advanced research and development, particularly focusing on its proprietary compounds, DA-1241 and DA-1726. These compounds are being developed for various indications, including metabolic syndrome and obesity.
| Compound | Indication | Phase of Development | Expected Completion |
|---|---|---|---|
| DA-1241 | Metabolic Syndrome | Phase 2a | Q4 2025 |
| DA-1726 | Obesity | Phase 1 | Q2 2025 |
Focus on Patient-Centric Solutions
NeuroBo's vision emphasizes a patient-centric approach, aiming to address unmet medical needs effectively. The company believes in developing treatments that not only target symptoms but also improve overall patient well-being. This approach is reflected in their ongoing clinical trials and the strategic partnerships they have formed to enhance their research capabilities.
Sustainable Growth and Collaboration
NeuroBo Pharmaceuticals is dedicated to sustainable growth, which includes strategic collaborations and partnerships. The company has secured a license agreement with Dong-A ST Co., Ltd., which enhances its development capabilities for DA-1241 and DA-1726. This collaboration aims to leverage shared expertise and resources, ensuring efficient clinical development.
| Partnership | Focus | Investment | Projected Impact |
|---|---|---|---|
| Dong-A ST Co., Ltd. | Technical Support and Manufacturing | $10 million | Accelerated Development Timeline |
Financial Aspirations
As of September 30, 2024, NeuroBo reported cash reserves of $21.7 million and an accumulated deficit of $130.7 million. The company's financial strategy includes raising additional funds through equity offerings and collaborations to support ongoing research and clinical trials.
| Financial Metric | Value (2024) |
|---|---|
| Cash Reserves | $21.7 million |
| Accumulated Deficit | $130.7 million |
| Net Loss (Nine Months) | $22.4 million |
Vision for 2025 and Beyond
Looking forward, NeuroBo Pharmaceuticals aims to enhance its position in the biopharmaceutical sector by continuing to innovate and expand its product pipeline. The company is focused on bringing its compounds to market, thereby contributing to the treatment landscape for metabolic and neurodegenerative diseases.
Core Values of NeuroBo Pharmaceuticals, Inc. (NRBO)
Innovation
NeuroBo Pharmaceuticals, Inc. (NRBO) places a strong emphasis on innovation as a core value, driving the development of transformative therapies. This commitment is evidenced by the substantial increase in research and development (R&D) expenses, which reached $17.5 million for the nine months ended September 30, 2024, a significant increase of 230.5% compared to $5.3 million for the same period in 2023. This growth reflects the company's focus on advancing its clinical trials for DA-1241 and DA-1726, which are pivotal to its therapeutic pipeline.
Integrity
Integrity is central to NeuroBo's operations, guiding its ethical conduct in clinical trials and business practices. The company has maintained a zero percent effective tax rate due to a full valuation allowance for its net operating losses, indicating a transparent approach to financial reporting. As of September 30, 2024, the accumulated deficit stood at $130.7 million, underscoring the company's commitment to ethical financial practices amid ongoing investments in R&D.
Collaboration
Collaboration is integral to NeuroBo's strategy, particularly through its partnerships with Dong-A ST Co., Ltd. Under a shared services agreement, NeuroBo incurred R&D expenses of $4.3 million related to this collaboration for the nine months ended September 30, 2024, compared to $2.2 million the previous year. This partnership enhances its capabilities in developing DA-1241 and DA-1726, demonstrating the value of collaborative efforts in achieving common goals.
Excellence
Excellence is a cornerstone of NeuroBo's mission, reflected in its rigorous clinical trial processes. The company's total operating expenses for the nine months ended September 30, 2024, were $23.2 million, a 127.3% increase from $10.2 million in 2023, indicating a relentless pursuit of high-quality research outcomes. The ongoing Phase 2a clinical trial for DA-1241 represents a significant step towards demonstrating excellence in therapeutic development.
Accountability
NeuroBo emphasizes accountability by maintaining robust governance structures to oversee its operations. As of September 30, 2024, the company reported a cash balance of $21.7 million, which is expected to fund its operations into the third quarter of 2025. This financial stewardship is crucial for ensuring that resources are allocated effectively to support ongoing and future clinical trials.
| Core Value | Example Initiative | Financial Impact (2024) |
|---|---|---|
| Innovation | Increased R&D spending | $17.5 million |
| Integrity | Zero effective tax rate | Accumulated deficit: $130.7 million |
| Collaboration | Partnership with Dong-A | R&D expenses: $4.3 million |
| Excellence | Ongoing Phase 2a trial | Total operating expenses: $23.2 million |
| Accountability | Financial management | Cash balance: $21.7 million |
NeuroBo Pharmaceuticals, Inc. (NRBO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- NeuroBo Pharmaceuticals, Inc. (NRBO) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of NeuroBo Pharmaceuticals, Inc. (NRBO)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View NeuroBo Pharmaceuticals, Inc. (NRBO)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.